A Study to Assess the Adverse Events and How Oral ABBV-1042 Moves Through the Body of Healthy Adult Participants

Part of paid clinical trials in Grayslake, Illinois.

Sponsor
AbbVie
Study ID
NCT07222709
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

  • Healthy Volunteer

Eligibility Criteria

Sex
ALL
Age
18 Years - 55 Years
Healthy Volunteers
Accepted

Interventions

  • ABBV-1042 — DRUG
    Oral Solution
  • Placebo — DRUG
    Oral Solution

Study Details

This study will assess the adverse events, tolerability, and how oral ascending doses of ABBV-1042 moves through the body of healthy adult participants.

Key Dates

Start date
Oct 27, 2025
Status verified
Oct 2025
Primary completion
May 31, 2026
Completion
May 31, 2026

Study Design

Enrollment
48 participants (estimated)
Allocation
RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
BASIC_SCIENCE

Arms

  • Experimental: ABBV-1042 or Placebo-Group 1
    Participants will receive an oral dose of ABBV-1042 or placebo on day 1.
  • Experimental: ABBV-1042 or Placebo-Group 2
    Participants will receive an oral dose of ABBV-1042 or placebo on day 1.
  • Experimental: ABBV-1042 or Placebo-Group 3
    Participants will receive an oral dose of ABBV-1042 or placebo on day 1.
  • Experimental: ABBV-1042 or Placebo-Group 4
    Participants will receive an oral dose of ABBV-1042 or placebo on day 1.
  • Experimental: ABBV-1042 or Placebo-Group 5
    Participants will receive an oral dose of ABBV-1042 or placebo on day 1.
  • Experimental: ABBV-1042 or Placebo-Group 6
    Participants will receive an oral dose of ABBV-1042 or placebo on day 1.

Primary Outcome Measure

Number of Participants Experiencing Adverse Events [ Time Frame: Up to approximately 32 days ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Acpru /Id# 279405GrayslakeIllinois60030-

Find similar trials in Grayslake, IL

By research site
Acpru· Grayslake, IL

Related Studies